Reports Q1 revenue $300.4M vs. $164.3M last year. “We delivered a strong quarter with growth across all our key products,” said Joe Papa, President and CEO at Emergent. “We also took significant actions to improve our debt position, reduce operating expenses and strengthen our financial flexibility. Emergent’s transformation will not happen overnight. The actions we are implementing today, combined with the assets Emergent possesses, will enable us to move faster, reach farther and be more nimble. The public health threats we collectively face are changing, and so is Emergent.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent Biosolutions Adjusts Contract Terms and Preps Q1 Report
- Emergent BioSolutions Announces Restructuring and Cost-Saving Measures
- Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
- Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
- Emergent BioSolutions Announces Amendment to its Existing Credit Facility